Miguel Edwards is a Partner at DeciBio Consulting, where he specializes in the development, commercialization, and application of emerging tools and diagnostics. Edwards has extensive experience helping clients refine product specifications, and identify target markets, customers, and business models. He has had a hand in helping clients drive novel technologies and approaches to market including single-cell, spatial, next-generation sequencing, liquid biopsies, CRISPR, high-plex proteomic approaches, and noninvasive prenatal testing. Edwards exemplifies the firm's culture with his passion for the life sciences and an eagerness to see emerging technologies accelerate innovation in precision medicine.
DeciBio, a top-ranked firm on Vault, participates across the precision medicine value chain, providing a uniquely comprehensive perspective on how market developments propagate throughout the entire ecosystem. DeciBio provides 1) bespoke, comprehensive consulting services to provide market clarity and inform strategic decisions, 2) custom and off-the-shelf market intelligence and analytics tools and data sets to provide novel insights, and 3) strategic advisory and capital contributions for pre-series A precision medicine startups. Edwards attends and speaks at several industry and investor conferences; and participates in DeciBio's investing activities. He holds a PhD in molecular biology from UCLA.
